1 / 2

Intensity-Modulated Proton Therapy

Intense-modulated Proton Treatment (IMPT) is a novel combination chemotherapy drug that targets low-intensity cancer cells by coupling electron-doping and proton-proton binding.

Download Presentation

Intensity-Modulated Proton Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Coherent Market Insights Intensity-modulated proton treatment has risen in popularity as a result of its high precision, efficiency, and safety. Intense-modulated Proton Treatment (IMPT) is a novel combination chemotherapy drug that targets low-intensity cancer cells by coupling electron-doping and proton-proton binding. The drug, named IMPT 189 (Chloroquine), binding DNA directly by an intramuscular triterpenoid ligand. The ligand, selected for its affinity to the nucleic acid, modulates the DNA transcription factor, resulting in inhibition or activation of the affected genes. Intensity-modulated Proton Therapy is a targeted therapy, which means it is only effective if the particular mass is the target of the therapy. If the patient has a primary mass, such as a bone tumor, ovarian cyst or small-intestinal stromal tumor, Intense Modulated Proton Therapy may not be successful. Since this is the case, the Intense Modulated Proton Therapy information panel in figure 1, states, "The majority of patients with large tumors (over 5 cm) have been successfully treated using this technology". This implies that for patients with a primary mass, such as an ovarian cyst, a biopsy of that mass is usually sufficient to determine whether Intense Modulated Proton Therapy is indicated, and then either IMPT or BTP may be used. Intensive therapy is Coherent Market Insights

  2. Coherent Market Insights required if the patient is showing signs of portal vein tumor despite the presence of another portal vein tumor or in the peritoneal cavity. Read More : https://bit.ly/2TCzRwI Coherent Market Insights

More Related